Search

Your search keyword '"Sabahat Alisir Ecder"' showing total 6 results
Start Over Author "Sabahat Alisir Ecder"
6 results on '"Sabahat Alisir Ecder"'

1. Latent Tuberculosis Infection Management in Solid Organ Transplantation Recipients: A National Snapshot

Author

Aylin Özgen Alpaydın, Tuba Yeter Turunç, Vildan Avkan-Oğuz, Füsun Öner-Eyüboğlu, Elif Tükenmez-Tigen, İmran Hasanoğlu, Güle Aydın, Yasemin Tezer-Tekçe, Seniha Şenbayrak, Filiz Kızılateş, Adalet Altunsoy Aypak, Sibel Altunışık-Toplu, Pınar Ergen, Behice Kurtaran, Meltem Işıkgöz Taşbakan, Ayşegül Yıldırım, Serkan Yıldız, Kenan Çalışkan, Ebru Ayvazoğlu, Ender Dulundu, Ebru Şengül Şeref Parlak, İrem Akdemir, Melih Kara, Sinan Türkkan, Kübra Demir-Önder, Ezgi Yenigün, Aslı Turgut, Sabahat Alışır Ecder, Saime Paydaş, Tansu Yamazhan, Tufan Egeli, Rüya Özelsancak, Arzu Velioğlu, Mehmet Kılıç, Alpay Azap, Erdal Yekeler, Tuğrul Çakır, Yaşar Bayındır, Asiye Kanbay, Ferit Kuşcu, Kemal Osman Memikoğlu, Nazan Şen, Erhan Kabasakal, and Gülden Ersöz

Subjects
Medicine
Abstract

OBJECTIVE: Latent tuberculosis infection (LTBI) screening is strongly recommended in the pre-transplant evaluation of solid organ transplant (SOT) recipients, although it remains inadequate in many transplant centers. We decided to investigate pre-transplant TB risk assessment, LTBI treatment, and registry rates in Turkey. MATERIAL AND METHODS: Adult SOT recipients who underwent tuberculin skin test (TST) and/or interferon-gamma release test (IGRA) from 14 centers between 2015 and 2019 were included in the study. An induration of ≥5 mm on TST and/or probable/positive IGRA (QuantiFERON-TB) was considered positive for LTBI. Demographic features, LTBI screening and treatment, and pre-/post-transplant TB history were recorded from the electronic database of transplantation units across the country and pooled at a single center for a unified database. RESULTS: TST and/or IGRA were performed in 766 (33.8%) of 2266 screened patients most of whom were kidney transplant recipients (n = 485, 63.4%). LTBI screening test was positive in 359 (46.9%) patients, and isoniazid was given to 203 (56.5%) patients. Of the patients treated for LTBI, 112 (55.2%) were registered in the national registry, and 82 (73.2%) completed the treatment. Tuberculosis developed in 6 (1.06%) of 563 patients who were not offered LTBI treatment. CONCLUSION: We determined that overall, only one-third of SOT recipients in our country were evaluated in terms of TB risk, only 1 of the 2 SOT recipients with LTBI received treatment, and half were registered. Therefore, we want to emphasize the critical importance of pretransplant TB risk stratification and registration, guided by revised national guidelines.

Published
2024
Full Text
View/download PDF

3. MO166: The Longitudinal Evolution of Covid-19 Outcomes Among Hemodialysis Patients: A Nationwide Multicentre Controlled Study

Author

Savas Ozturk, Kenan Turgutalp, Mustafa Arici, Numan Gorgulu, Halil Zeki Tonbul, Necmi Eren, Vedat Gencer, Deniz Ayli, Irem Pembegul, Murside Esra Dolarslan, Zeynep Ural, Hulya Colak, Tuba Elif Ozler, Ozgur Can, Mehmet Emin Demir, Orcun Altunoren, Bulent Huddam, Kursad Onec, Bülent Demirelli, Zeki Aydin, Eda Altun, Selma Alagoz, Yavuz Ayar, Zeynep Ebru Eser, Bayram Berktaş, Zulfukar Yilmaz, Eser Uslu Ates, Enver Yuksel, Gizem Kumru Sahin, Merve Aktar, Egemen Cebeci, Belda Dursun, Sibel Yucel Kocak, Abdulmecit Yildiz, Sinan Kazan, Mahmut Gok, Sengul Erkan, Murat Tugcu, Ramazan Ozturk, Serdar Kahvecioglu, Ekrem Kara, Bulent Kaya, Garip Sahin, Tamer Sakaci, Savas Sipahi, Ilhan Kurultak, Beyza Algül Durak, Mehmet Riza Altiparmak, Sabahat Alisir Ecder, Serhat Karadag, Mevlut Tamer Dincer, Hakan Ozer, Sibel Bek, Sena Ulu, Ozkan Gungor, Elif Ari Bakir, Ali Riza Odabas, Nurhan Seyahi, Alaattin Yildiz, and Kenan Ateş

Subjects
Transplantation, Nephrology
Abstract

BACKGROUND AND AIMS Haemodialysis (HD) patients are at increased risk for adverse short-term consequences of COVID-19. In this study, we investigated the characteristics of chronic HD patients in the post-COVID-19 period and compared them with the control group. METHOD We conducted a national multicentre observational study involving adult chronic HD patients recovering from COVID-19. The control HD group was selected from patients with similar characteristics who did not have COVID-19 in the same center. SARS-CoV-2 RT-PCR negative patients and patients in the active period of COVID-19 were not included. RESULTS A total of 1223 patients (635 COVID-19 groups, 588 control groups) were included in the study from the data collected from 47 centres between 21 April 2021 and 11 June 2021. The patients' baseline demographics, comorbidities, medications, HD characteristics and basic laboratory tests were quite similar between the groups (Table 1). 28th-day mortality and between 28th day and 90th day mortality were higher in the COVID-19 group than in the control group [19 (3.0%) patients and 0 (0%) patients; 15 (2.4%) patients and 4 (0.7%) patients, respectively]. Presence of respiratory symptoms, rehospitalization, need for home oxygen therapy, lower respiratory tract infection and A-V fistula thrombosis were significantly higher in the COVID-19 group in the first 28 days of illness and between 28 and 90 days. Mortality was significantly associated with preexisting COVID-19, age, current smoking, use of tunneled HD catheter, persistence of respiratory symptoms, rehospitalization, need for home oxygen support, presence of lower respiratory tract infection within 28 days and persistence of respiratory symptoms. CONCLUSION In the post-COVID-19 period, mortality, rehospitalization, respiratory problems and vascular access problems are higher in maintenance HD patients who have had COVID-19 compared to control HD patients. Table 2. Comparative presentation of patients data on the 28th day and between 28 and 90 day COVID-19 groupN = 635 Control groupN = 588 28th-day results, n(%) Death* 19(3.0) 0(0) Any respiratory symptoms* 152(23.9) 11(1.9) Rehospitalization for any reason* 52(8.2) 24(4.1) Need for home oxygen support * 26(4.1) 2(0.3) Lower respiratory tract infection* 65(10.2) 8(1.4) AV fistula thrombosis* 13(2.0) 2(0.3) Other thromboembolic events * 15(2.4) 4(0.7) Need for HD catheter placement* 21(3.3) 9(1.5) 28th day-90. day resultsa n(%) N:616 N:588 Death* 15(2.4) 4(0.7) Any respiratory symptoms* 45(7.3) 10(1.7) Rehospitalization for any reason* 44(7.1) 18(3.1) Need for home oxygen support* 12(1.9) 2(0.3) AV fistula thrombosis* 9(1.5) 1(0.2) Other thromboembolic events* 9(1.5) 2(0.3) Need for HD catheter placement 13(2.1) 10(1.7) HD: haemodialysis, AV: arteriovenous. *P

Published
2022
Full Text
View/download PDF

4. The Longitudinal Evolution of Post-COVID-19 Outcomes Among Hemodialysis Patients in Turkey

Author

Savas Ozturk, Kenan Turgutalp, Mustafa Arici, Numan Gorgulu, Halil Zeki Tonbul, Necmi Eren, Vedat Gencer, Mehmet Deniz Ayli, Irem Pembegul, Murside Esra Dolarslan, Zeynep Ural, Hulya Colak, Tuba Elif Ozler, Ozgur Can, Mehmet Emin Demir, Orcun Altunoren, Bulent Huddam, Kursad Onec, Bulent Demirelli, Zeki Aydin, Eda Altun, Selma Alagoz, Yavuz Ayar, Zeynep Ebru Eser, Bayram Berktas, Zulfukar Yilmaz, Eser Uslu Ates, Enver Yuksel, Gizem Kumru Sahin, Merve Aktar, Egemen Cebeci, Belda Dursun, Sibel Yucel Kocak, Abdulmecit Yildiz, Sinan Kazan, Mahmut Gok, Erkan Sengul, Murat Tugcu, Ramazan Ozturk, Serdar Kahvecioglu, Ekrem Kara, Bulent Kaya, Garip Sahin, Tamer Sakaci, Savas Sipahi, Ilhan Kurultak, Beyza Algul Durak, Mehmet Riza Altiparmak, Sabahat Alisir Ecder, Serhat Karadag, Mevlut Tamer Dincer, Hakan Ozer, Sibel Gokcay Bek, Memnune Sena Ulu, Ozkan Gungor, Elif Ari Bakir, Ali Riza Odabas, Nurhan Seyahi, Alaattin Yildiz, Kenan Ates, Pembegül, İrem, MÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Huddam, Bülent, RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, and Kara, Ekrem

Subjects
Mortality-Rates, hemodialysis, Nephrology, Hemodialysis, Nationwide study, outcome, COVID-19, OVID-19, nationwide study, Transplant, Outcome
Abstract

Introduction: Hemodialysis (HD) patients have increased risk for short-term adverse outcomes of COVID-19. However, complications and survival at the post-COVID-19 period have not been published extensively.Methods: We conducted a national, multicenter observational study that included adult maintenance HD patients recovered from confirmed COVID-19. A control HD group without COVID-19 was selected from patients in the same center. We investigated the characteristics and outcomes in the follow-up of HD patients and compare them with the non-COVID-19 group.Results: A total of 1223 patients (635 patients in COVID-19 group, 588 patients in non-COVID-19 group) from 47 centers were included in the study. The patients' baseline and HD characteristics were almost similar. The 28th-day mortality and mortality between 28th day and 90th day were higher in the COVID-19 group than non-COVID-19 group (19 [3.0%] patients vs. none [0%]; 15 [2.4%] patients vs. 4 [0.7%] patients, respectively). The presence of respiratory symptoms, rehospitalization, need for home oxygen therapy, lower respiratory tract infection, and arteriovenous (AV) fistula thrombosis was significantly higher in the COVID-19 group in both the first 28 days and between 28 and 90 days. In the multivariable analysis, age (odds ratio [OR] [95% CI]: 1.029 [1.004-1.056]), group (COVID-19 group vs. non-COVID-19 group) (OR [95% CI]: 7.258 [2.538-20.751]), and vascular access type (tunneled catheter/AV fistula) (OR [95% CI]: 2.512 [1.249-5.051]) were found as independent parameters related to 90-day mortality.Conclusion: In the post-COVID-19 period, maintenance HD patients who have had COVID-19 have increased rehospitalization, respiratory problems, vascular access problems, and high mortality compared with the non-COVID-19 HD patients.

Published
2022

5. Surveillance of hemodialysis related infections: a prospective multicenter study

Author

Imran Hasanoglu, Rahmet Guner, Suzan Sahin, Fatma Yılmaz Karadag, Ergun Parmaksiz, H. Veli Atalay, Sabahat Alısır Ecder, Tugba Arslan Gulen, Zuhal Atan Ucar, Oguz Karabay, Savas Sipahi, Esra Kaya Kılıc, Murat Duranay, Derya Yapar, İbrahim Dogan, Gulden Ersoz, Gulcan Turkmen, and Ahmet Alper Kıykım

Subjects
Medicine, Science
Abstract

Abstract As in many countries, there is neither a surveillance system nor a study to reveal the hemodialysis (HD) related infection rates in Turkey. We aimed to investigate the infection rate among HD outpatients and implement CDC’s surveillance system. A multicenter prospective surveillance study is performed to investigate the infection rate among HD patients. CDC National Healthcare Safety Network (NHSN) dialysis event (DE) protocol is adopted for definitions and reporting. During April 2016–April 2018, 9 centers reported data. A total of 199 DEs reported in 10,035 patient-months, and the overall DE rate was 1.98 per 100 patient-months. Risk of blood culture positivity is found to be 17.6 times higher when hemodialysis was through a tunneled catheter than through an arteriovenous fistula. DE rate was significantly lower in patients educated about the care of their vascular access site. Staphylococcus aureus was the most causative microorganism among mortal patients. Outcomes of DEs were hospitalization (73%), loss of vascular access (18.2%), and death (7.7%). This first surveillance study revealed the baseline status of HD related infections in Turkey and showed that CDC National Healthcare Safety Network (NHSN) DE surveillance system can be easily implemented even in a high workload dialysis unit and be adopted as a nationwide DE surveillance program.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results